[
    {
        "id": "osp-2545",
        "type": "article-journal",
        "title": "Why Intralesional Measles-Mumps-Rubella is Superior to Bacillus Calmette-Guérin for Treatment of Warts?",
        "author": [
            {
                "family": "Al-Qassabi",
                "given": "Al Mutasim"
            },
            {
                "family": "Al Kindi",
                "given": "Abdulrahman"
            }
        ],
        "URL": "https://omanscience.com/en/articles/why-intralesional-measles-mumps-rubella-is-superior-to-bacillus-calmette-guerin-for-treatment-of-warts",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2022
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2022.95",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "We thank Dr. Al-Mendalawi for his valuable comments. We agree that there are multiple therapies available for the treatment of warts. Regarding the Bacillus Calmette-Guérin (BCG) vaccine, recent studies showed that the measles-mumps-rubella (MMR) vaccine has superior or comparative results to BCG. Moreover, BCG needs a prior Mantoux test and is considered unsafe in a tuberculosis-endemic area, making the choice of using MMR superior to BCG. Measurement of Th1 and Th2 cytokines during various intralesional immunotherapies is non-practical and unnecessary. Besides, it needs specialized labs which are not available in most settings. There is no definite follow-up period for patients with warts, but a period of three to six months is considered appropriate. In fact, both patients were followed further after publishing the cases and there is no recurrence to date."
    }
]